Title Money Today -- LegoChem filed a patent for BLI in America

Publication: Money Today / Dong Hee Kim

Date: 15 October 2015

Summary

• LegoChem Biosciences filed a patent in America for LCB18-0064, a Beta-Lactamase candidate substance.

• LegoChem suffered in 2012 due to Astrazeneca cancelling their contract as they pulled out their antibiotic projects. However, LegoChem focused on developing BLI candidate substance and was able to turn the suffering to their advantage.

• CEO Yong Zu Kim said, "After the contract with Astrazeneca was cancelled last April, we quickly formed a research team to develop BLI and recently earned a tangible result."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).